Publications by authors named "Michael Butticello"

Claim this Profile
I
Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer.
Shane O'Brien, Michael Butticello, Christine Thompson, Boris Wilson, Anastasia Wyce

BMC Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-Based Drug Discovery: Identification and Optimization of Small Molecules that Reduce -MYC Protein Levels in Cells.
Jesús R Medina, Xinrong Tian, William H Li, Dominic Suarez, James F Mack, Michael Butticello

J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Andrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, Sarah V Gerhart, Lorna H Mitchell, Michael Butticello

Cancer Cell· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Helai P Mohammad, Kimberly N Smitheman, Chandrashekhar D Kamat, David Soong, Kelly E Federowicz, Michael Butticello

Cancer Cell· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis